Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that João Siffert, M.D., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 8:30 a.m. ET in New York City.
A live webcast will be available in the investor section of the company’s website at www.designtx.com. The webcast will be archived for 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.
Contact:
Investors:
Chelcie Lister
THRUST Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.04 |
| Daily Change: | -0.13 -3.12 |
| Daily Volume: | 65,794 |
| Market Cap: | US$229.350M |
April 21, 2025 March 10, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
